Conventional and genetic evidence on the association between adiposity and chronic kidney disease

Conventional and genetic evidence on the association between adiposity and chronic kidney disease

<p><strong>Background:</strong> The size of any causal contribution of central and general adiposity to chronic kidney disease (CKD) risk and the underlying mechanism of mediation are unknown.</p> <p><strong>Methods:</strong> 281,228 UK Biobank participants...

Full description

Bibliographic Details
Main Authors:	Zhu, P, Herrington, W, Haynes, R, Emberson, J, Landray, M, Baigent, C, Lewington, S, Staplin, N
Format:	Journal article
Language:	English
Published:	American Society of Nephrology 2020

Similar Items

Conventional and genetic evidence on the association between adiposity and CKD
by: Zhu, P, et al.
Published: (2020)

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
by: Zhu, P, et al.
Published: (2020)

Evidence for the prevention and treatment of stroke in dialysis patients
by: Herrington, W, et al.
Published: (2014)

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease
by: Herrington, W, et al.
Published: (2016)

Determining the relationship between blood pressure, kidney function, and chronic kidney disease: insights from genetic epidemiology
by: Staplin, N, et al.
Published: (2022)

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
by: Mayne, K, et al.
Published: (2024)

Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease
by: Mihaylova, B, et al.
Published: (2019)

Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease
by: Mayne, K, et al.
Published: (2023)

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
by: Staplin, N, et al.
Published: (2023)

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
by: Herrington, W, et al.
Published: (2022)

Use of causal diagrams to inform the analysis and interpretation of observational studies: An example from the Study of Heart and Renal Protection (SHARP)
by: Staplin, N, et al.
Published: (2016)

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
by: Herrington, WG, et al.
Published: (2023)

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
by: Haynes, R, et al.
Published: (2018)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
by: Herrington, W, et al.
Published: (2018)

Neprilysin inhibition in chronic kidney disease.
by: Judge, P, et al.
Published: (2014)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
by: Schlackow, I, et al.
Published: (2017)

Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP).
by: Haynes, R, et al.
Published: (2014)

Evaluating the contribution of the cause of kidney disease to prognosis in ckd: Results from the Study of Heart and Renal Protection (SHARP)
by: Haynes, R, et al.
Published: (2014)

Benefits of lowering cholesterol in chronic kidney disease Reply
by: Baigent, C, et al.
Published: (2011)

Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease
by: Zhu, D, et al.
Published: (2025)

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
by: Mayne, KM, et al.
Published: (2024)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: Results from the study of heart and renal protection
by: Reith, C, et al.
Published: (2017)

Kidney disease trials for the 21st century: innovations in design and conduct
by: Herrington, W, et al.
Published: (2019)

Chronic kidney disease, heart failure and neprilysin inhibition
by: Haynes, R, et al.
Published: (2019)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection
by: C. Reith, et al.
Published: (2017-05-01)

Which cardiovascular risk factors matter in chronic kidney disease?
by: Baigent, C, et al.
Published: (2007)

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.
by: Mafham, M, et al.
Published: (2017)

Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD
by: Lamprea-Montealegre, J, et al.
Published: (2019)

Biliary tract and liver complications in polycystic kidney disease
by: Judge, P, et al.
Published: (2017)

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
by: Storey, B, et al.
Published: (2018)

Lipids in chronic kidney disease.
by: Lewis, D, et al.
Published: (2010)

Commentary: Controversies in NICE guidance on chronic kidney disease.
by: Landray, M, et al.
Published: (2008)

Commentary: Controversies in NICE guidance on chronic kidney disease
by: Landray, M, et al.
Published: (2008)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
by: Storey, B, et al.
Published: (2017)

Allocated but not treated: the silent 16% – Authors' reply
by: Horby, P, et al.
Published: (2022)

Use of gel-based separator tubes to stabilise phosphate in mailed blood samples.
by: Herrington, W, et al.
Published: (2015)

Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: the EMPA-KIDNEY trial
by: Preiss, D, et al.
Published: (2022)

Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: a randomised double-blind trial
by: Haynes, R, et al.
Published: (2018)

The role of lipoprotein(a) in chronic kidney disease
by: Hopewell, J, et al.
Published: (2018)

Empagliflozin in patients with chronic kidney disease
by: Herrington, WG, et al.
Published: (2022)